Prof. Sven Francque, Chair of the PanNASH initiative reviews the current management options in NASH and the many molecules in development. It sheds light on the rationale for PPAR agonists as a promising and very valuable therapeutic option with systemic potential, for what happens in the liver and outside of the liver.
That’s a very important concept because lipotoxicity is…
Discover the progresses of the quest for biomarkers in NASH with Prof Szabo
Prevalence of NAFLD (non-alcoholic fatty liver disease) affects…
So NAFLD (non-alcoholic fatty liver disease) is a…
June 12 is dedicated to increasing awareness about non-alcoholic steatohepatitis, or NASH, among various populations: the general public, at-risk patients, the medical community, public health authorities, and the media.
Prof Jean-François Dufour, Switzerland sheds lights on this important question.
Prof Pierre-Emmanuel Rautou, Paris, France highlights two important abstracts presented in Boston during the Liver meeting 2019.